Antitumor effect of combination of S-1 and docetaxel on the human breast cancer xenograft transplanted into SCID mice

Oncology Reports

Volumn 15, Issue 6, 2006, Pages 1517-1522

  Suto, Akihiko ^a,b   Kubota, Tetsuro ^a,d   Fukushima, Masakazu ^c   Ikeda, Tadashi ^a   Takeshita, Toshio ^b   Ohmiya, Harumi ^b   Kitajima, Masaki ^a  

^a KEIO UNIVERSITY   (Japan)

^b Yamato Municipal Hospital   (Japan)

^c TAIHO PHARMACEUTICAL CO LTD   (Japan)

^d KEIO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Breast cancer; Combination therapy; Docetaxel; DPD inhibitory fluoropyrimidine; S 1

Indexed keywords

ANTINEOPLASTIC AGENT; DIHYDROURACIL DEHYDROGENASE; DOCETAXEL; OXONIC ACID; S 1 (COMBINATION); TAXOID; TEGAFUR; THYMIDYLATE SYNTHASE;

ANIMAL; ARTICLE; BREAST TUMOR; DRUG ANTAGONISM; DRUG COMBINATION; DRUG POTENTIATION; DRUG SCREENING; ENZYMOLOGY; FEMALE; HUMAN; METABOLISM; MOUSE; MOUSE MUTANT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NAD+); DRUG COMBINATIONS; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICE, SCID; OXONIC ACID; TAXOIDS; TEGAFUR; THYMIDYLATE SYNTHASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33748977873     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.6.1517     Document Type: Article

References (38)

1. Mansour EG, Gray R, Shatila AH, Tormey DC, Cooper MR, Osborne CK and Falkson G: Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis - an intergroup study. J Clin Oncol 16: 3486-3492, 1998. (Pubitemid 28506758)
2. Goldhirsch A, Glick JH, Gelber RD and Seen HJ: Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 90: 1601-1608, 1998. (Pubitemid 28523434)
3. O'Shaughnessy J, Miles D, Vukelja S, Maiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Hazel GV, Verma S and Leonard R: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trials results. J Clin Oncol 20: 2812-2823, 2002. (Pubitemid 34651510)
4. Nagashima F, Ohtsu A, Yoshida S and Ito K: Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer. Gastric Cancer 8: 6-11, 2005. (Pubitemid 40394918)
5. Schöffski P: The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs 15: 85-106, 2004.
6. Saeki T, Takashima S, Sano M, Horikoshi N, Miura S, Shimizu S, Morimoto K, Kimura M, Aoyama H, Ota J, Noguchi S and Taguchi T: A phase II study of S-1 in patients with metastatic breast cancer - a Japanese trial by the S-1 cooperative study group, breast cancer working group. Breast Cancer 11: 194-202, 2004.
7. Yoshida K, Hirabayashi N, Takiyama W, Ninomiya M, Takakura N, Sakamoto J, Nishiyama M and Toge T: Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer. Anticancer Res 24: 1843-1852, 2004.
8. O'Brien ME, Leonard RC, Barrett-Lee PJ, Eggleton SP and Bizzari JP: Docetaxel in the community setting: an analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. UK Study Group. Ann Oncol 10: 205-210, 1999. (Pubitemid 29113181)
9. Kouroussis C, Androulakis N, Kakolyris S, Souglakos J, Kotsakis T, Mavroudis D, Katsogridakis K, Vardakis N, Hatzidaki D, Samonis G, Vlachonikolis J and Georgoulias V: Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer. J Clin Oncol 17: 862-869, 1999. (Pubitemid 29109316)
10. Ravdin PM, Burris HA, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E and Bellet RE: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13: 2879-2885, 1995.
11. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschênes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JWR, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PSGJ, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Riva A, Aapro M and 304 Study Group: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17: 1413-1424, 1999. (Pubitemid 29220847)
12. Sjöström J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lonn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjovall M, Wist E, Valvere V, Anderson H and Bergh J: Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomized phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35: 1194-1201, 1999. (Pubitemid 29359178)
13. Bonneterre J, Roche H, Monnier A, Guastalla JP, Namer M, Fargeot P and Assadourian S: Docetaxel vs. 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 87: 1210-1215, 2002. (Pubitemid 36009124)
14. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS and Griffin T: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17: 485-493, 1999. (Pubitemid 29075232)
15. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A and Osterwalder B: Multicenter phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma. Cancer 92: 1759-1768, 2001. (Pubitemid 32952493)
16. Nukatsuka M, Fujioka A, Nakagawa F, Oshimo H, Kitazato K, Uchida J, Sugimoto Y, Nagayama S and Fukushima M: Antimetastatic and anticancer activity of S-1, a new oral dihydro-pyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model. Int J Oncol 25: 1531-1536, 2004.
17. Nukatsuka M, Fujioka A, Nakagawa F and Fukushima M: Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in murine model of breast cancer metastatic to the lung. Jpn J Cancer Chemother 29: 95-101, 2002 (In Japanese).
18. Geran RI, Greenberg NH, Schumacher AM and Abbott BJ: Protocols for screening chemical agents and natural products against animal tumors and other biological systems (third edition). Cancer Chemother Rep 3: 51-61, 1972.
19. Fukushima M, Satake H, Uchida J, Shimosato Y, Kato T, Takechi T, Okabe H, Fujioka A, Nakano K, Ohshimo H, Takeda S and Shirasaka T: Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts Int J Oncol 13: 693-698, 1998.
20. Ouch-Fujimoto K, Tanaka Y and Tominaga T: Schedule dependency of antitumor activity in combination therapy with capecitabine/5′-deoxy-5- fluorouridine and docetaxel in breast cancer models. Clin Cancer Res 7: 1079-1086, 2001. (Pubitemid 32708748)
21. Spears CP, Shahinian AH, Moran RG, Heidelberg C and Corbett TH: In vitro kinetics of thymidylate synthase inhibition in 5-fluorouracil-sensitive and resistant murine colon adenocarcinomas. Cancer Res 42: 450-456, 1982. (Pubitemid 12173578)
22. Naguib FNM, El-Kouni MH and Cha S: Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res 45: 5405-5412, 1985. (Pubitemid 16200794)
23. Takechi T, Uchida J, Fujioka A and Fukushima M: Enhancing 5-fluorouracil cytotoxicity by inhibiting dihydropyrimidine dehydrogenase activity with uracil in human tumor cells. Int J Oncol 11: 1041-1044, 1997. (Pubitemid 27439412)
24. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720, 1998. (Pubitemid 28474225)
25. Koizumi W, Kurihara M, Nakano S and Hasegawa K: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 58: 191-197, 2000. (Pubitemid 30189900)
26. Taguchi T, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J and Hirabayashi N: Late phase II clinical study of RP56976 (Docetaxel) in patients with advanced/recurrent gastric cancer: A Japanese cooperative study group trial(Group A). Jpn J Cancer Chemother 25: 1915-1924, 1998 (In Japanese).
27. Mai M, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J, Hirabayashi N, Taguchi T and Furue H: A late phase II clinical study of RP56976 (Docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (Group B). Jpn J Cancer Chemother 26: 487-496, 1999 (In Japanese).
28. Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, Wanders KJ, Franklin H, LeBail N and Verwij J for the EPRTC Clinical Trial Group: Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer 70: 380-383, 1994.
29. Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, Miyata Y and Taguchi T: Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reaction. Ann Oncol 12: 1133-1137, 2001. (Pubitemid 32834495)
30. Trudeau ME: Docetaxel (Taxotere): an overview of first-line monotherapy. Semin Oncol 22: 17-21, 1995.
31. Isobe Y, Kubota T, Asanuma F, Kurihara H, Inada T, Fukutomi T, Ishibiki K and Abe O: Pharmacodynamic aspects of in vitro and in vivo chemosensitivity tests. Jpn J Cancer Res 78: 983-990, 1987. (Pubitemid 17151575)
32. Takahashi I, Emi Y, Kakeji Y, Uchida J, Fukushima M and Maehara Y: Increased antitumor activity in combined treatment TS-1 and docetaxel: a preclinical study using gastric cancer xenografts. Oncology 68: 130-137, 2005. (Pubitemid 41158968)
33. Takeda Y, Yoshizaki I, Nonaka Y, Yanagie H, Matsuzawa A and Eriguchi M: Docetaxel alone or orally combined with 5-fluorouracil and its derivatives: effects on mouse mammary tumor cell line MM2 in vitro and in vivo. Anticancer Drugs 12: 691-698, 2001. (Pubitemid 32844210)
34. Mori K, Hasegawa M, Nishida M, Toma H, Fukuda M, Kubota T, Nagasue N, Yamana H, Hirakawa-YS, Chung K, Ikeda T, Takasaki K, Oka M, Kameyama M, Toi M, Fujii H, Kitamura M, Murai M, Sasaki H, Ozono S, Makuuchi H, Shimada Y, Onishi Y, Aoyagi S, Mizutani K, Ogawa M, Nakao A, Kinoshita H, Tono T, Imamoto H, Nakashima Y and Manabe T: Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int J Oncol 17: 33-38, 2000.
35. Ikeguchi M, Hirooka Y, Makino M and Kaibara N: Dihydropyrimidine dehydrogenase activity of cancerous and non-cancerous tissues in liver and large intestine. Oncol Rep 8: 621-625, 2001. (Pubitemid 33758465)
36. Anan K, Mitsuyama S, Tamae K, Suehara N, Nishihara K, Ogawa Y, Abe Y, Iwashita T and Toyoshima S: Increased dihydropyrimidine dehydrogenase activity in breast cancer. J Surg Oncol 82: 174-179, 2003. (Pubitemid 36278265)
37. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Takechi T, Okabe H, Fukushima M and Kitajima M: Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil. Jpn J Cancer Res 91: 105-112, 2000. (Pubitemid 30128944)
38. Okitsu H, Umemoto A, Honda J, Okitsu N, Seike J, Tanida N and Monden Y: Induction of TP and DPD expression by docetaxel and doxifluridine (5′-DFUR) in gastric cancer. Nippon Rinsyo Gekagakkai-shi 65: 587-593, 2004 (In Japanese).